Author

N. E. Brunk

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

D. M. Walden· 1 shared H. Hou· 1 shared J. Varshney· 1 shared K. Chakravarty· 1 shared M. Khotimchenko· 1 shared M. S. Hixon· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

6 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

D. M. Walden

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Combinatorial approaches using an AI/ML-driven drug development platform targeting insulin resistance, lipid dysregulation, and inflammation for the amelioration of metabolic syndrome in patients

M. Khotimchenko, M. S. Hixon, N. E. Brunk, D. M. Walden, H. Hou, K. Chakravarty, J. Varshney

The paper proposes a combinatorial drug approach using FDA-approved compounds targeting IL-17a and DPP4 to treat metabolic syndrome, using an AI/ML platform to identify promising drug candidates.

bioRxiv · Sep 1, 2021 · PreprintPharmacology & Toxicology